SEC Form 4 · accession 0001144204-15-043795
Aevi Genomic Medicine, Inc. · GNMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Barbara Gayle Duncan
Director
Period of report
Jul 22, 2015
Accepted (ET)
Jul 23, 2015 · 8:30 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001138776
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option Award (Right to buy) | $8.09 | Jul 22, 2015 | A | 20,000 | A | Jul 22, 2016 | Jul 22, 2025 | Common Stock | 20,000 | 20,000 | D |